Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Pentoxifylline and Covid-19: A Systematic Review

View ORCID ProfileDiego Ramonfaur, View ORCID ProfileCarlos A. González-Assad, View ORCID ProfileJosé G. Paredes-Vázquez
doi: https://doi.org/10.1101/2020.09.14.20194381
Diego Ramonfaur
1Instituto de Cardiología y Medicina Vascular, Escuela de Medicina y Ciencias de la Salud. Monterrey, Mexico.
2School of postgraduate education, Harvard Medical School, Boston, MA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Diego Ramonfaur
  • For correspondence: dramonfaur@hms.harvard.edu
Carlos A. González-Assad
1Instituto de Cardiología y Medicina Vascular, Escuela de Medicina y Ciencias de la Salud. Monterrey, Mexico.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Carlos A. González-Assad
José G. Paredes-Vázquez
1Instituto de Cardiología y Medicina Vascular, Escuela de Medicina y Ciencias de la Salud. Monterrey, Mexico.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for José G. Paredes-Vázquez
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

At more than 10 months after the first case of COVID-19 was documented, the understanding of the pathogenesis of this viral illness is growing on a daily basis. A massive pro-inflammatory response on infected individuals involving several cytokines seems to play a key role on disease. As a result, therapeutic efforts have focused on anti-inflammatory strategies to ameliorate the disease, in sight of a lack of a truly effective anti-viral agent. Pentoxifylline (PTX) has been proposed by multiple authors as a potential therapeutic ally, targeting a variety of mechanisms as it has been shown to have antiviral, anti-inflammatory and hemodynamic effects. Importantly, anti-inflammatory effects center on down-regulation of cytokines such as interleukins and tumor necrosis factor. In pre-pandemic studies, PTX has demonstrated to change the clinical course of inflammatory diseases such as acute respiratory distress syndrome, which is a hallmark of severe COVID-19. Researchers agree it is pertinent to experimentally evaluate the effect this drug has on COVID-19 patients. The objective of this review is to summarize all the proposed mechanisms by which PTX may aid in the treatment of COVID-19, as well as prevent its deadly complications. Our interpretation of the literature is that the benefits PTX may bring to a patient with COVID-19 outweigh the risks this drug might pose on them. As a result, there is consensus regarding the evaluation of PTX in further experimental studies to better characterize its effects on COVID-19 patients.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not request or receive any funding.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Does not apply

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • The authors declare no conflict of interest

  • This study did not request or receive any funding.

Data Availability

N/a

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted September 18, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Pentoxifylline and Covid-19: A Systematic Review
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Pentoxifylline and Covid-19: A Systematic Review
Diego Ramonfaur, Carlos A. González-Assad, José G. Paredes-Vázquez
medRxiv 2020.09.14.20194381; doi: https://doi.org/10.1101/2020.09.14.20194381
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Pentoxifylline and Covid-19: A Systematic Review
Diego Ramonfaur, Carlos A. González-Assad, José G. Paredes-Vázquez
medRxiv 2020.09.14.20194381; doi: https://doi.org/10.1101/2020.09.14.20194381

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (227)
  • Allergy and Immunology (502)
  • Anesthesia (110)
  • Cardiovascular Medicine (1234)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (530)
  • Epidemiology (10015)
  • Forensic Medicine (5)
  • Gastroenterology (499)
  • Genetic and Genomic Medicine (2448)
  • Geriatric Medicine (236)
  • Health Economics (479)
  • Health Informatics (1638)
  • Health Policy (751)
  • Health Systems and Quality Improvement (636)
  • Hematology (248)
  • HIV/AIDS (532)
  • Infectious Diseases (except HIV/AIDS) (11862)
  • Intensive Care and Critical Care Medicine (625)
  • Medical Education (252)
  • Medical Ethics (74)
  • Nephrology (268)
  • Neurology (2278)
  • Nursing (139)
  • Nutrition (350)
  • Obstetrics and Gynecology (453)
  • Occupational and Environmental Health (534)
  • Oncology (1245)
  • Ophthalmology (375)
  • Orthopedics (133)
  • Otolaryngology (226)
  • Pain Medicine (155)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (729)
  • Pharmacology and Therapeutics (311)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2280)
  • Public and Global Health (4829)
  • Radiology and Imaging (834)
  • Rehabilitation Medicine and Physical Therapy (490)
  • Respiratory Medicine (651)
  • Rheumatology (283)
  • Sexual and Reproductive Health (237)
  • Sports Medicine (226)
  • Surgery (266)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)